Copyright
        ©The Author(s) 2017.
    
    
        World J Gastroenterol. Jun 7, 2017; 23(21): 3864-3875
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3864
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3864
		Figure 1 Differential serum miRNA expression levels in non-infected healthy controls compared to hepatocellular carcinoma patients.
		
			
		
	
		Figure 2 Efficacy of studied miRNAs in hepatocellular carcinoma non-malignant differentiation using receiver operating characteristics curve analysis.
		
			 Hepatocellular carcinoma (HCC) (n = 224) and healthy control (n = 84).
		
	
		Figure 3 Efficacy of studied miRNAs in hepatocellular carcinoma, hepatitis C virus categorization using receiver operating characteristics curve analysis.
		
			 Hepatocellular carcinoma (n = 224) and hepatitis C virus (n = 250). AUC: Area under the curve.
		
	
		Figure 4 Diagnostic activity of the panel of miRNAs studied.
		
			
		
	
		Figure 5 Comparison between miRNA panel and alpha-fetoprotein using receiver operating characteristic curve.
		
			 AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.
		
	
- Citation: Elemeery MN, Badr AN, Mohamed MA, Ghareeb DA. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. World J Gastroenterol 2017; 23(21): 3864-3875
 - URL: https://www.wjgnet.com/1007-9327/full/v23/i21/3864.htm
 - DOI: https://dx.doi.org/10.3748/wjg.v23.i21.3864
 
